NEKTAR THERAPEUTICS — Director's Dealing 2017

Jul 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2017-07-11

Reporting Person: Gergel Ivan P. (SVP & Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-07-11	Common Stock	M	8389	$11.04	Acquired	51961	Direct
2017-07-11	Common Stock	S	8389	$21.04	Disposed	43572	Direct
2017-07-12	Common Stock	M	36691	$11.04	Acquired	80263	Direct
2017-07-12	Common Stock	S	36691	$21.09	Disposed	43572	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-07-11	Stock Option	$11.04	M	8389	Disposed	2022-05-18	Common Stock (8389)	Direct
2017-07-12	Stock Option	$11.04	M	36691	Disposed	2022-05-18	Common Stock (36691)	Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This transaction was executed in multiple trades at prices ranging from $21.04 to $21.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F3: This transaction was executed in multiple trades at prices ranging from $21.04 to $21.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.